I am a medical oncologist who specializes in creating cutting-edge treatments for patients with lung cancer. This is a disease with unacceptable outcomes, but there are many promising therapies today and on the horizon. I was named to the Castle Connolly list of “America’s Top Doctors” from 2004 to 2019 and rated in the top 10 percent of physicians in the nation for patient satisfaction in 2016.

I serve as a professor of internal medicine at The Ohio State University and co-leader of the Translational Therapeutics Program at the OSUCCC – James, where I also direct the Thoracic Oncology Center. In addition, I am the president of the International Association for the Study of Lung Cancer (IASLC) and hold the Barbara J. Bonner Chair in Lung Cancer Research.

My research is focused specifically on proteomic and expression array signature development, genetics, immunotherapy and tumor-associated immunosuppression mechanisms in lung cancer. Some of my recent research directions include the development of molecular biomarkers to guide patient management and therapy, and molecular profiling of lung cancers and pre-neoplasias to guide the development of therapeutics, especially using mass spectrometry-based proteomics.

I’ve served as an investigator on multiple clinical trials, including the large phase III lung cancer trials, for the Eastern Cooperative Oncology Group (ECOG), one of the largest clinical cancer research organizations in the U.S. Additionally, I’ve authored more than 250 peer-reviewed publications, book chapters and articles. I have served on several National Cancer Institute (NCI) grant review panels and the NCI Board of Scientific Counselors. I am also a past president of the International Association for the Study of Lung Cancer and current co-chair of the NCI CTEP Thoracic Malignancies Steering Committee.

In 2012, I came to Ohio State from Vanderbilt University to establish and direct the OSUCCC – James thoracic center. With our multidisciplinary team approach, we apply advanced molecular diagnostics and state-of-the-art therapeutics to provide personalized care every lung cancer patient.

The collaborative spirit, team approach, dedicated patient care and enlightened leadership we enjoy at the OSUCCC – James all come together together to make this a great place to work and a great place to receive treatment for cancer.